New 'Sandwich' therapy aims to stop leukemia relapse after transplant
NCT ID NCT06985498
First seen Mar 28, 2026 · Last updated May 02, 2026 · Updated 3 times
Summary
This study tests a new treatment plan for young adults and adults with B-cell acute lymphoblastic leukemia (B-ALL). The approach uses immunotherapy before an autologous stem cell transplant, followed by a 'sandwich' of two types of CAR-T cells (CD22 and CD19) to try to prevent the cancer from coming back. The goal is to see if this strategy is safe and helps people live longer without leukemia returning. About 40 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBKASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.